Compile Data Set for Download or QSAR
Report error Found 226 Enz. Inhib. hit(s) with all data for entry = 11765
TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645536(US20240018122, Example 71 | 3-(4-{2-[(4-{[6-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645537(US20240018122, Example 72 | 2-(4-{2-[(4-{[6-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645538(US20240018122, Example 73 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645539(US20240018122, Example 75 | 2-{[2-(4-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645532(US20240018122, Example 66 | 7-{2-[4-(2-aminoethyl)...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645533(US20240018122, Example 67 | N-[2-(4-{2-[(4-{[6-(5-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645534(US20240018122, Example 68 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645535(US20240018122, Example 69 | N-[2-(4-{2-[(4-{[6-(5-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645544(US20240018122, Example 89 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645545(US20240018122, Example 90 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645546(US20240018122, Example 112 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645547(US20240018122, Example 114 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645540(US20240018122, Example 77 | methyl N-[2-(4-{2-[(4-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645541(US20240018122, Example 81 | 4-{[6-(5-chloro-2-fluo...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645542(US20240018122, Example 86 | 3-(4-{2-[(4-{[6-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645543(US20240018122, Example 87 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645520(US20240018122, Example 37 | N-{6-[2-fluoro-5-(prop...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645521(US20240018122, Example 41 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645522(US20240018122, Example 42 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645523(US20240018122, Example 48 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645516(US20240018122, Example 30 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645517(US20240018122, Example 32 | N-(4-{[6-(5-chloro-2-f...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645518(US20240018122, Example 35 | 1-(4-{2-[(4-{[6-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645519(US20240018122, Example 36 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645528(US20240018122, Example 61 | 4-{[6-(5-chloro-2-fluo...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645529(US20240018122, Example 62 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645530(US20240018122, Example 63 | 3-(4-{2-[(4-{[6-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645531(US20240018122, Example 64 | 4-{[6-(5-chloro-2-fluo...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645524(US20240018122, Example 52 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645525(US20240018122, Example 55 | N-[6-(5-chloro-2-fluor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645526(US20240018122, Example 56 | 1-(3-{2-[(4-{[6-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645527(US20240018122, Example 60 | methyl 3-(4-{2-[(4-{[6...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645551(US20240018122, Example 133 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645552(US20240018122, Example 134 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645553(US20240018122, Example 137 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645554(US20240018122, Example 148 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645547(US20240018122, Example 114 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645548(US20240018122, Example 115 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645549(US20240018122, Example 118 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645550(4-{[6-(5-chloro-2-fluorophen- yl)-3-methylpyridazi...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645559(US20240018122, Example 165 | methyl 4-{[6-(5-chlor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645560(US20240018122, Example 171 | methyl 4-{[6-(5-chlor...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645561(US20240018122, Example 177 | [6-(5-chloro-2-fluoro...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645562(US20240018122, Example 183 | N-[6-(5-chloro-2-fluo...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645555(US20240018122, Example 152 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645556(US20240018122, Example 153 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645550(4-{[6-(5-chloro-2-fluorophen- yl)-3-methylpyridazi...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645550(4-{[6-(5-chloro-2-fluorophen- yl)-3-methylpyridazi...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645552(US20240018122, Example 134 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645553(US20240018122, Example 137 | 4-{[6-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
US Patent

Displayed 1 to 50 (of 226 total ) | Next | Last >>
Jump to: